Eloxx Pharmaceuticals Inc Topline ELX-02 Phase 2 Combination Results Call Transcript
Good afternoon. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Eloxx Pharmaceuticals Conference Call. (Operator Instructions) Mr. John Woolford, Head of Investor Relations, you may begin your conference.
Thank you, operator. Good afternoon, and thank you to everyone who has joined today's call and webcast to discuss topline ELX-02 cystic fibrosis Phase II combination clinical trial results. A press release detailing the results was issued this afternoon and is currently available at www.eloxxpharma.com. An audio archive of the webcast will be available on Eloxx Pharmaceuticals website in the Investor Relations section later today. Also, please note that there are slides to accompany today's event. These slides are also available on the IR website.
Before we begin with prepared remarks, turning to Slide 2, I need to remind you that we will be making forward-looking statements during this teleconference that
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |